News
-
-
-
COMMUNIQUÉ DE PRESSE
FY 2024/25: BRAIN Biotech AG benefits from successful monetization of projects and strong corporate cost control
BRAIN Biotech AG reports FY 2024/25 financial results showing successful project monetization and cost control measures. Decline in revenues offset by strong cash position -
-
-
COMMUNIQUÉ DE PRESSE
BRAIN Biotech AG appoints Johan Jansén-Storbacka as Executive Vice President of the BRAINBiocatalysts´ enzyme products business
BRAIN Biotech AG appoints Johan Jansén-Storbacka as Executive Vice President of the BRAINBiocatalysts´ enzyme products business on September 1, 2025, succeeding Rod Sears-Black. Johan brings 20+ years of biotechnology experience -
-
-
-